| Hey traders, Lance Ippolito here! Welcome to our Weekly Rundown, where we'll share some of our top trading ideas — and our biggest winners!
Alternative drug developer Mind Medicine Inc. (Nasdaq: MNMD) debuted on the Nasdaq on Tuesday following an incredible two-day run-up that saw the stock jump over 47%.
MindMed is a biotechnology company focused on the clinical development of psychedelic-sourced drugs.
This is a big win for the alternative pharmaceutical space after years of struggling for mainstream recognition.
The medical and business communities are beginning to realize that treatments like psilocybin, ketamine and DMT can help with mental disorders like anxiety, depression and trauma.
According to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults.
So Is MindMed a Buy?
Personally, I'm excited about MindMed's debut. Not only because I think this company has a lot of potential, but also because it signals a change in how alternative medicine is viewed.
Finally, the "magic mushroom sector," which I like to call alternative medicine, is getting a nod from Big Pharma. Thursday, this stock was trading around $4 to $5, and I'm curious if we're going to start to see more institutional investment and so it can begin trading like a real company.
I think it can.
If you look back at the early days of the cannabis sector, it had a lot of the same stigmas that these psychedelics companies do. But as social and legal acceptance grew, companies like Canopy Growth Corp. (NYSE: CGC) shot up about 4,500%...
This is a sign of a gradual acceptance of alternative medicine, and MindMed could be one of the winners of that movement over the long haul.
BIG Wins
We had a few more big winners this week from our Weekly Blitz Alerts trading strategy. The first was a final close-out trade on last week's monster run on Under Armour Inc. (NYSE: UAA) contracts.
We closed the remaining balance before earnings after an amazing run. Even though it was possible that UAA could trade higher on earnings, the stock was up so much since the entry, with shares printing over $24, I was more than happy to take profits of 173% on this leg. Part of risk management means not getting greedy!
- +172.73% on the third leg of UAA (May 7 $21.50 CALL).
- Entered on April 20 at $1.10 a contract.
- Exited on April 27 at $3.00 a contract
On Monday, Ryder System Inc. (NYSE: R) saw two orders of call buyers with 2,000-plus contracts trading after the United Parcel Service, Inc. (NYSE: UPS) earnings report shot that stock higher. Traders then started betting for upside in R as well. On Wednesday, we took profits on half of the position at $3.10 before they jumped another 65% the next day!
- +88.4% on our second half of R (May 21 $77.50 CALL).
- Entered on Apr. 27 at $2.60 a contract.
- Exited on Apr. 29 at $4.90 a contract
On Thursday, 3,000 FireEye Inc. (Nasdaq: FEYE) May expiration calls were bought at $0.99, with repeat buying after. That morning, there were over 5,000 of these calls trading. Implied volatility was cheap in-the-money calls after a two day sell-off. Then 30 minutes after my alert, FEYE was mentioned on TV as shares rallied over 3.5%, moving the stock to $20.15 for a sweet 50% pop in the options.
- +50% on our first half of FEYE (May 21 $19 CALL).
- Entered on Apr. 29 at $1.00 a contract.
- Exited on Apr. 29 at $1.50 a contract
If you have a big score you'd like to share with your fellow Future of Wealth readers, email us your screenshots of the trade and/or any details you want to share at wptestimonial@gmail.com, and we'll celebrate them here!
Cash in on the Next Electric Vehicle Wave
The first wave of riches came from Tesla's historic two-year run… which not only triggered a new wave of "Teslanaires," but led an entire shift in how we look at transportation.
For early investors who act fast, this opportunity couldn't be more lucrative.
A perfect storm is brewing between the biggest automotive companies in the world right now...
Signing Off
If you're looking for more compelling trade ideas and stock market musings to read and help you prepare for what lies ahead, here's what other experts at WealthPress are saying:
| 
0 Response to "Weekly Rundown: Is This New ‘Alternative Medicine’ Stock a Buy?"
Post a Comment